Nemolizumab Prurigo Nodularis 24-Week Real-World Data: PP-NRS 8.1→1.8. Trial Efficacy Replicated in Real Patients
A new standard in chronic itch is being validated by real-world data. The 24-week real-world analysis published in the Journal of Dermatological Treatment May 2026 reported that 38 prurigo nodularis patients receiving nemolizumab (Nemluvio) 60mg subcutaneous → PP-NRS (Peak Pruritus Numerical Rating Scale) dropped from average 8.1 to 1.8 at week 8 + stable through week 24. The efficacy of OLYMPIA 1·2 trials replicated in real-practice settings.
What Is Prurigo Nodularis
Prurigo nodularis is a skin disease characterized by chronic intense itch + thick nodular lesions formed by repetitive scratching. Predominantly female (60~70%). Clinical features:
- PP-NRS 8~10 (10-point scale): very severe itch
- 10~hundreds of nodules: distributed on extensor extremities, back, shoulders
- Sleep disturbance: 90%+ patients affected by nocturnal itch
- Quality of life impact: average DLQI (Dermatology Life Quality Index) 16+ (very severe)
- Chronic course: progresses 5~10 years after onset
- Limited standard treatment efficacy: topical steroids, antihistamines, gabapentin, pregabalin all weak
Reasons for female predominance:
- Co-occurring chronic allergy·atopic
- Hormone fluctuation (especially menopause)
- Co-occurring autoimmunity (thyroid etc.)
- Co-occurring chronic stress·depression
How Nemolizumab Works
Nemolizumab is a humanized IgG2 monoclonal antibody blocking IL-31 receptor alpha (IL-31RA). IL-31 is a type 2 immune cytokine and central mediator of itch signaling.
Action circuit:
- IL-31 blockade: directly binds IL-31RA → blocks signal transduction
- Itch signal blockade: reduces itch stimulation of cutaneous nerve fibers
- Itch-scratch-inflammation cycle break: chronic circuit recovery
- Gradual nodule recovery: 8~24 week cumulative
From OLYMPIA Trials to Real-World
OLYMPIA 1·2 (phase 3, 2024):
- 270 prurigo nodularis patients
- Patient proportion with PP-NRS ≥4 reduction at 16 weeks: 56
58% (vs placebo 2122%) - IGA 0/1 (clear/almost clear) achievement: 33~38%
- 2024 FDA·EMA approval
JDermTreatment 2026 real-world (24 weeks):
- 38 patients (single-center retrospective)
- PP-NRS average 8.1 → week 8: 1.8 → week 24: 1.5 stable
- Itch reduction starting day 2 (17.2% patients)
- Gradual nodule count reduction
- Very high patient satisfaction
- Side effects: similar to placebo
Real-world data replicates trial efficacy + extends to 24 weeks. Some patients showed faster response than in trials.
Indication Expansion
Current FDA approval (2024):
- Prurigo nodularis (adult)
- Atopic dermatitis (adult moderate to severe)
2026 AAD release (Galderma):
- Children (2~11 years) atopic dermatitis trial results favorable
- Indication expansion application in progress
Under research:
- Chronic urticaria
- Other chronic itch beyond nodular itch
- Cutaneous T-cell lymphoma associated itch
Dose·Administration
Prurigo nodularis:
- 30mg subcutaneous → every 4 weeks
- 60mg loading dose initially
- Self-injection possible (pen format)
Atopic dermatitis:
- 60mg subcutaneous → every 4 weeks
- Self-injection possible
Evaluation timing: clear itch reduction at week 4, meaningful nodule·EASI score improvement at week 8~16, cumulative effect at week 24+.
Side Effects·Cautions
OLYMPIA + real-world combined:
- Headache: in some patients (5~10%)
- Injection site reaction: mild
- Conjunctivitis: in some (in atopic dermatitis trials)
- Upper respiratory infection: in some
- Serotonin level changes: signal reported in trials but clinical meaning undefined
- Pregnancy·lactation: data lacking, caution
Cost·Accessibility
- US market price: $5,000+/month
- Korean market entry: 2025 MFDS approval. Insurance coverage in process. Specialty disease cost reimbursement for prurigo nodularis indication under review
- Out-of-pocket: ₩2,000,000–4,000,000/month (pre-insurance)
- With insurance: estimated ₩300,000–600,000/month
Comparison with Dupilumab
| Aspect | Nemolizumab (Nemluvio) | Dupilumab (Dupixent) |
|---|---|---|
| Target | IL-31RA | IL-4Rα (IL-4 + IL-13) |
| Action | Direct itch blockade | Chronic inflammation + barrier recovery |
| Rapid itch effect | ✓✓ (day 2~) | ✓ (1~2 weeks) |
| Nodule recovery | 8~16 weeks | 8~16 weeks |
| Indications | Prurigo nodularis, AD | AD, asthma, EoE, nasal polyps, broad |
| Dosing | Every 4 weeks | Every 2 weeks |
| Korean entry | 2025 | 2017 |
Selection criteria:
- Itch dominant + prurigo nodularis: nemolizumab 1st line
- Chronic inflammation + barrier damage + co-itch: dupilumab 1st line
- Insufficient dupilumab response + residual itch: add/switch nemolizumab
Clinical Significance in Korea
Korean prurigo nodularis patients:
- Exact prevalence absent (under-diagnosed)
- Estimated adult 0.5~1%
- Female predominant
- Onset in matrix of chronic allergy·atopy + menopausal hormone fluctuation + chronic stress
Nemolizumab introduction is the first dedicated drug for prurigo nodularis. Clear standard for patients previously stuck with detour treatments (topical + antihistamines + gabapentin).
Natural Matrix (Concurrent)
Beyond standard nemolizumab drug, matrix:
- Barrier moisturization: ceramide·cholesterol·hyaluronic acid topical
- Avoid irritants: too-hot water·irritating soap avoidance
- Chronic stress management: itself stimulates itch circuits
- Sleep recovery: nocturnal itch → sleep deprivation → immune balance worsening cycle
- Omega-3 + vitamin D: chronic inflammation attenuation
- GOS·fermented foods: gut-skin axis (microbiome → IL-31)
- Skin microbiome protection: avoid irritating antibiotic cosmetics
Conclusion
Nemolizumab 24-week real-world data clearly validates the clinical efficacy of IL-31 blocking drugs. Settling as the first dedicated drug in areas where standard treatment was weak, like prurigo nodularis. An option that can seriously address the clinical burden of female-predominant + chronic itch + broad quality-of-life impact. Combination of natural matrix + standard drug matrix is the new standard for chronic skin immune diseases.